What Comes Next? Strategies for COVID-19 Vaccine Development

It has been more than a hundred days since Chinese researchers posted the genetic sequence for the SARS-CoV2 virus to a public database, setting off the biggest and fastest race to create vaccines the world has ever seen. One of the defining features of the race is diversity -- of vaccine modalities, types of organizations developing them, and geographic distribution of R&D and manufacturing. So far, at least six vaccines have made it into the clinic. We have reached the end of the beginning: What comes next?

In this exclusive webinar, BioCentury, BioKatalyst and Lonza bring together industry and policy leaders to discuss how to accelerate COVID-19 vaccine development.

Session Chair
Steve Usdin
Washington Editor

Pierre Catignol.jpg
Pierre Catignol
Site Head
Lonza Portsmouth (NH), USA
Bill Enright 100x115.jpg
William “Bill” Enright
Director and CEO
Vaccitech, Ltd.
Nicole Lurie70x96.jpg
Nicole Lurie, M.D., M.S.P.H.
Strategic Advisor, CEPI (The Coalition for Epidemic Preparedness Innovation); and former Assistant Secretary for Preparedness and Response, U.S. Department of Health and Human Services
Xuefeng Yu Photo100.jpg
Xuefeng YU, Ph.D
Co-founder, Chairman and CEO
CanSino Biologics Inc. 

Organized by:
BC BK.jpg
In collaboration with:


Webinar Registration